Baseline mineralizing surface determines the magnitude of the bisphosphonate effect on cortical bone mineralization in postmenopausal osteoporotic patients

Barbara Misof Misof, S. Blouin, S. Lueger, E. P. Paschalis, Robert R. Recker, R. Phipps, K. Klaushofer, P. Roschger

Research output: Contribution to journalArticle

Abstract

Purpose: To determine the effect of short- or long-term bisphosphonate treatment on cortical bone mineralization density distribution (BMDD). Methods: BMDD was assessed by quantitative backscatter electron imaging in postmenopausal osteoporosis: in paired transiliac biopsy samples (n=36) at baseline and after 3 years risedronate treatment from a clinical study, in transiliac biopsy samples from patients who were treated with either risedronate (n=31) or alendronate (n=68) for 3 to 7 years from an observational study. Outcomes were related to premenopausal reference data (n=73) and to histomorphometric mineralizing surface per bone surface (MS/BS). Results: In the clinical study, patients with lower (below cohort median) MS/BS had normal cortical CaMean at baseline. After 3 years risedronate, their CaMean was not different versus baseline but increased versus reference (+2.9%, p=0.003). Among the groups of the observational study, CaMean did not exceed reference level, was similar for alendronate versus risedronate and similar between 3 to 5 years versus longer than 5 years treatment duration. Conclusion: Baseline bone mineralizing surface appears to be important for the effect of bisphosphonate on cortical bone mineralization. In patients with lower baseline MS/BS, level of mineralization after treatment can exceed reference level. Whether this is beneficial in the long-term is unknown.

Original languageEnglish (US)
Pages (from-to)183-191
Number of pages9
JournalJournal of Musculoskeletal Neuronal Interactions
Volume17
Issue number3
StatePublished - Sep 1 2017

Fingerprint

Physiologic Calcification
Diphosphonates
Bone and Bones
Alendronate
Bone Density
Observational Studies
Biopsy
Postmenopausal Osteoporosis
Therapeutics
Electrons
Risedronate Sodium
Cortical Bone
Clinical Studies

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Orthopedics and Sports Medicine

Cite this

Baseline mineralizing surface determines the magnitude of the bisphosphonate effect on cortical bone mineralization in postmenopausal osteoporotic patients. / Misof, Barbara Misof; Blouin, S.; Lueger, S.; Paschalis, E. P.; Recker, Robert R.; Phipps, R.; Klaushofer, K.; Roschger, P.

In: Journal of Musculoskeletal Neuronal Interactions, Vol. 17, No. 3, 01.09.2017, p. 183-191.

Research output: Contribution to journalArticle

Misof, Barbara Misof ; Blouin, S. ; Lueger, S. ; Paschalis, E. P. ; Recker, Robert R. ; Phipps, R. ; Klaushofer, K. ; Roschger, P. / Baseline mineralizing surface determines the magnitude of the bisphosphonate effect on cortical bone mineralization in postmenopausal osteoporotic patients. In: Journal of Musculoskeletal Neuronal Interactions. 2017 ; Vol. 17, No. 3. pp. 183-191.
@article{091a977ef16044d1aa4be64d69012e4d,
title = "Baseline mineralizing surface determines the magnitude of the bisphosphonate effect on cortical bone mineralization in postmenopausal osteoporotic patients",
abstract = "Purpose: To determine the effect of short- or long-term bisphosphonate treatment on cortical bone mineralization density distribution (BMDD). Methods: BMDD was assessed by quantitative backscatter electron imaging in postmenopausal osteoporosis: in paired transiliac biopsy samples (n=36) at baseline and after 3 years risedronate treatment from a clinical study, in transiliac biopsy samples from patients who were treated with either risedronate (n=31) or alendronate (n=68) for 3 to 7 years from an observational study. Outcomes were related to premenopausal reference data (n=73) and to histomorphometric mineralizing surface per bone surface (MS/BS). Results: In the clinical study, patients with lower (below cohort median) MS/BS had normal cortical CaMean at baseline. After 3 years risedronate, their CaMean was not different versus baseline but increased versus reference (+2.9{\%}, p=0.003). Among the groups of the observational study, CaMean did not exceed reference level, was similar for alendronate versus risedronate and similar between 3 to 5 years versus longer than 5 years treatment duration. Conclusion: Baseline bone mineralizing surface appears to be important for the effect of bisphosphonate on cortical bone mineralization. In patients with lower baseline MS/BS, level of mineralization after treatment can exceed reference level. Whether this is beneficial in the long-term is unknown.",
author = "Misof, {Barbara Misof} and S. Blouin and S. Lueger and Paschalis, {E. P.} and Recker, {Robert R.} and R. Phipps and K. Klaushofer and P. Roschger",
year = "2017",
month = "9",
day = "1",
language = "English (US)",
volume = "17",
pages = "183--191",
journal = "Journal of Musculoskeletal Neuronal Interactions",
issn = "1108-7161",
publisher = "International Society of Musculoskeletal and Neuronal Interactions",
number = "3",

}

TY - JOUR

T1 - Baseline mineralizing surface determines the magnitude of the bisphosphonate effect on cortical bone mineralization in postmenopausal osteoporotic patients

AU - Misof, Barbara Misof

AU - Blouin, S.

AU - Lueger, S.

AU - Paschalis, E. P.

AU - Recker, Robert R.

AU - Phipps, R.

AU - Klaushofer, K.

AU - Roschger, P.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Purpose: To determine the effect of short- or long-term bisphosphonate treatment on cortical bone mineralization density distribution (BMDD). Methods: BMDD was assessed by quantitative backscatter electron imaging in postmenopausal osteoporosis: in paired transiliac biopsy samples (n=36) at baseline and after 3 years risedronate treatment from a clinical study, in transiliac biopsy samples from patients who were treated with either risedronate (n=31) or alendronate (n=68) for 3 to 7 years from an observational study. Outcomes were related to premenopausal reference data (n=73) and to histomorphometric mineralizing surface per bone surface (MS/BS). Results: In the clinical study, patients with lower (below cohort median) MS/BS had normal cortical CaMean at baseline. After 3 years risedronate, their CaMean was not different versus baseline but increased versus reference (+2.9%, p=0.003). Among the groups of the observational study, CaMean did not exceed reference level, was similar for alendronate versus risedronate and similar between 3 to 5 years versus longer than 5 years treatment duration. Conclusion: Baseline bone mineralizing surface appears to be important for the effect of bisphosphonate on cortical bone mineralization. In patients with lower baseline MS/BS, level of mineralization after treatment can exceed reference level. Whether this is beneficial in the long-term is unknown.

AB - Purpose: To determine the effect of short- or long-term bisphosphonate treatment on cortical bone mineralization density distribution (BMDD). Methods: BMDD was assessed by quantitative backscatter electron imaging in postmenopausal osteoporosis: in paired transiliac biopsy samples (n=36) at baseline and after 3 years risedronate treatment from a clinical study, in transiliac biopsy samples from patients who were treated with either risedronate (n=31) or alendronate (n=68) for 3 to 7 years from an observational study. Outcomes were related to premenopausal reference data (n=73) and to histomorphometric mineralizing surface per bone surface (MS/BS). Results: In the clinical study, patients with lower (below cohort median) MS/BS had normal cortical CaMean at baseline. After 3 years risedronate, their CaMean was not different versus baseline but increased versus reference (+2.9%, p=0.003). Among the groups of the observational study, CaMean did not exceed reference level, was similar for alendronate versus risedronate and similar between 3 to 5 years versus longer than 5 years treatment duration. Conclusion: Baseline bone mineralizing surface appears to be important for the effect of bisphosphonate on cortical bone mineralization. In patients with lower baseline MS/BS, level of mineralization after treatment can exceed reference level. Whether this is beneficial in the long-term is unknown.

UR - http://www.scopus.com/inward/record.url?scp=85028748075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028748075&partnerID=8YFLogxK

M3 - Article

C2 - 28860420

AN - SCOPUS:85028748075

VL - 17

SP - 183

EP - 191

JO - Journal of Musculoskeletal Neuronal Interactions

JF - Journal of Musculoskeletal Neuronal Interactions

SN - 1108-7161

IS - 3

ER -